Early trial termination
RECRUITMENT
The first patient was randomized on 3 September 2020. Enrollment fluctuated with SARS-CoV-2 incidence in Germany. In January 2022, the Omicron variant became dominant in Germany. The neutralizing activity of stored plasma against Omicron was unknown. Also, enrollment had slowed considerably following new guidelines (from the World Health Organisation and others) on convalescent plasma use. The data-monitoring board thus recommended to stop recruitment, which was enacted on 20 January 2022, after enrollment of 77% of the target population.